2021
Targeting OCT3 attenuates doxorubicin-induced cardiac injury
Huang KM, Thomas M, Magdy T, Eisenmann ED, Uddin ME, DiGiacomo DF, Pan A, Keiser M, Otter M, Xia SH, Li Y, Jin Y, Fu Q, Gibson AA, Bonilla IM, Carnes CA, Corps KN, Coppola V, Smith SA, Addison D, Nies AT, Bundschuh R, Chen T, Lustberg MB, Wang J, Oswald S, Campbell MJ, Yan PS, Baker SD, Hu S, Burridge PW, Sparreboom A. Targeting OCT3 attenuates doxorubicin-induced cardiac injury. Proceedings Of The National Academy Of Sciences Of The United States Of America 2021, 118: e2020168118. PMID: 33495337, PMCID: PMC7865186, DOI: 10.1073/pnas.2020168118.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsChildDoxorubicinGene Expression RegulationHeart InjuriesHumansMiceMolecular Targeted TherapyMyocytes, CardiacNeoplasmsOrganic Anion Transporters, Sodium-IndependentPyrimidinesSequence Analysis, RNAConceptsOrganic cation transporter 3Cardiac injuryCardiovascular functionSide effectsTranslational relevanceCalcium-binding proteins S100A8Irreversible cardiac injuryCurrent preventative strategiesPotential translational relevanceCardiac damagePlasma levelsCardiac accumulationBreast cancerAntitumor effectsPharmacological targetingPreventative strategiesModest protectionProteins S100A8Critical transporterTransporter 3Pharmacological inhibitorsOverexpression modelIntervention strategiesDoxorubicinCardiotoxicity
2016
Pre-Hepatectomy Assessment of Bile Transporter Expression by Gadoxetic Acid-Enhanced MRI in a Rat Model of Liver Cirrhosis
Kim J, Kim T, Hong K, Moon H, Oh I, Lee S, Hohenwalter M, Zimmerman M, Cronin D, Hong J. Pre-Hepatectomy Assessment of Bile Transporter Expression by Gadoxetic Acid-Enhanced MRI in a Rat Model of Liver Cirrhosis. Journal Of Investigative Surgery 2016, 30: 265-271. PMID: 27780379, DOI: 10.1080/08941939.2016.1238983.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsATP-Binding Cassette TransportersGadolinium DTPAHepatectomyLiver Cirrhosis, ExperimentalMagnetic Resonance ImagingMaleOrganic Anion Transporters, Sodium-IndependentRats, Sprague-DawleyConceptsExpression of bile transportersGadoxetic acid-enhanced MRICirrhosis groupGadoxetic acidBile transportersMRNA expressionModel of liver cirrhosisDMN-induced liver injuryRat model of liver cirrhosisGroups of ratsMRNA expression ratioQuantify mRNA expressionMR signal intensityGE-MRIReal-time PCRContrast injectionLiver cirrhosisRat modelHepatocyte expressionTransporter expressionLiver injuryCirrhosisMRNA ratioRat liver tissueHepatobiliary system
2015
A Renal-Like Organic Anion Transport System in the Ciliary Epithelium of the Bovine and Human Eye
Lee J, Shahidullah M, Hotchkiss A, Coca-Prados M, Delamere NA, Pelis RM. A Renal-Like Organic Anion Transport System in the Ciliary Epithelium of the Bovine and Human Eye. Molecular Pharmacology 2015, 87: 697-705. PMID: 25661037, PMCID: PMC6067639, DOI: 10.1124/mol.114.096578.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiological Transport, ActiveCattleCiliary BodyDicarboxylic Acid TransportersHumansKidney CortexMultidrug Resistance-Associated ProteinsOrganic Anion Transport Protein 1Organic Anion TransportersOrganic Anion Transporters, Sodium-DependentOrganic Anion Transporters, Sodium-IndependentRetinal Pigment EpitheliumRNA, MessengerSymportersConceptsCiliary bodyAqueous humorPara-aminohippurateUssing chambersOcular tissuesReverse transcription-polymerase chain reactionOrganic anion transport systemHuman ocular tissuesBovine ciliary bodyHuman ciliary bodyPerfused eyePolymerase chain reactionBasolateral membraneEye preparationsTransporter expressionOrganic anion transportCiliary epitheliumAnion transport systemHuman eyeEpithelial cellsChain reactionBlood sideBlood directionEyesBarrier epithelia
2011
SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pomerantz M, Freedman M, Ross R, Regan M, Sharifi N, Figg W, Balk S, Brown M, Taplin M, Oh W, Lee G, Kantoff P. SLCO2B1 and SLCO1B3 May Determine Time to Progression for Patients Receiving Androgen Deprivation Therapy for Prostate Cancer. Journal Of Clinical Oncology 2011, 29: 2565-2573. PMID: 21606417, PMCID: PMC3138634, DOI: 10.1200/jco.2010.31.2405.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAndrogen AntagonistsAndrogensAntineoplastic Agents, HormonalBiological TransportDehydroepiandrosterone SulfateDisease ProgressionDisease-Free SurvivalDNA Mutational AnalysisDrug Resistance, NeoplasmGenotypeGonadotropin-Releasing HormoneHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasms, Hormone-DependentOrchiectomyOrganic Anion TransportersOrganic Anion Transporters, Sodium-IndependentPolymorphism, Single NucleotideProstatic NeoplasmsSolute Carrier Organic Anion Transporter Family Member 1B3TestosteroneConceptsAndrogen deprivation therapyTime to progressionShorter time to progressionProstate cancerDeprivation therapyProstate cancer treated with androgen deprivation therapyResistance to androgen deprivation therapyGenetic variantsAssociated with time to progressionMedian time to progressionAdvanced prostate cancerGene-gene interactionsSingle nucleotide polymorphismsPharmacogenomic determinantsSLCO2B1 genotypeEnhanced cell growthTransports androgensSLCO1B3 genotypesEfficient importNucleotide polymorphismsSLCO2B1Biological functionsAndrogenCell growthProstate
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply